Study	T2DM	Total MAFLD HCC		Proportion	95%-CI	Weight
Liu (2022)	30	176		0.17	[0.12; 0.23]	8.9%
Xiong (2022)	26	117		0.22	[0.15; 0.31]	8.7%
Xie (2022)	31	135		0.23	[0.16, 0.31]	8.8%
Xiong (2022)	28	114		0.25	[0.17; 0.34]	8.7%
Xue (2022)	43	169		0.25	[0.19; 0.33]	8.9%
Lin (2021)	117	369		0.32	[0.27, 0.37]	9.2%
Yun (2022)	2,294	6,790		0.34	[0.33; 0.35]	9.4%
Kim (2022)	137	325		0.42	[0.37; 0.48]	9.2%
Shaikh (2022)	8,620	18,839		0.46	[0.45; 0.46]	9.4%
Vitale (2023)	2,400	4,705		0.51	[0.50; 0.52]	9.4%
Myers (2021)	290	430		0.67	[0.63; 0.72]	9.2%
Random effects model		32,169		0.35	[0.26; 0.44]	100.0%

Heterogeneity: I^2=99%, τ^2=0.0251, P<0.01

A

Study	T2DM	Single-MAFLD HCC		Proportion	95%-CI	Weight
Xie (2022)	31	135		0.23	[0.16, 0.31]	20.0%
Liu (2022)	18	67		0.27	[0.17, 0.39]	19.4%
Vitale (2023)	803	1,181		0.68	[0.65; 0.71]	20.5%
Shaikh (2022)	2,935	4,234		0.69	[0.68; 0.71]	20.5%
Myers (2021)	54	74		0.73	[0.61; 0.83]	19.5%
Random effects model		5,691		0.52	[0.30; 0.74]	100.0%

Heterogeneity: I^2=98%, τ^2=0.0644, P<0.01

B

| Study	T2DM	Mixed-MAFLD HCC		Proportion	95%-CI	Weight
Liu (2022)	30	176		0.17	[0.12; 0.23]	10.8%
Xiong (2022)	26	117		0.22	[0.15; 0.31]	10.5%
Xue (2022)	43	169		0.25	[0.19; 0.33]	10.8%
Lin (2021)	117	369		0.32	[0.27, 0.37]	11.2%
Yun (2022)	2,294	6,790		0.34	[0.33; 0.35]	11.5%
Shaikh (2022)	5,685	14,789		0.38	[0.38; 0.39]	11.5%
Kim (2022)	137	325		0.42	[0.37; 0.48]	11.1%
Vitale (2023)	1,597	3,524		0.45	[0.44; 0.47]	11.5%
Myers (2021)	192	289		0.66	[0.61; 0.72]	11.1%
Random effects model		26,548		0.36	[0.26; 0.45]	100.0%

Heterogeneity: I^2=97%, τ^2=0.0230, P<0.01

C

Supplementary Figure 2. Forrest plots and pooled prevalence of T2DM in all individuals with MAFLD-HCC (A), single-aetiology MAFLD-HCC (B), and mixed-aetiology MAFLD HCC (C). T2DM, type 2 diabetes mellitus; MAFLD, metabolic dysfunction-associated fatty liver disease; HCC, hepatocellular carcinoma; CI, confidence interval.